
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is well-positioned to succeed as it approaches the launch of its proprietary psilocybin formulation, COMP360, which addresses the significant unmet need for treatment-resistant depression (TRD). The company is experiencing strong prescriber intent and has initiated the rolling submission of its new drug application (NDA), with a commercially favorable expected label and a manageable REMS process. COMPASS's other mental health indications, such as PTSD and anorexia nervosa, are also progressing towards potential future market opportunities, providing additional potential upside for the company's growth. Financially, COMPASS has a strong cash position and a well-built launch base for COMP360, positioning it for potential success upon FDA approval.
Bears say
Compass Pathways is operating in a relatively new and emerging market, which brings a high level of uncertainty and risk. Their success is heavily dependent on the results of their ongoing clinical trials, which could have a significant impact on their financial performance. Additionally, while there may be potential for expansion into other indications, it is still uncertain and could pose a risk if their treatments are not successful in these areas. It is important for investors to carefully consider these risks before investing in Compass Pathways.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares